News Conference News ACC 2024 TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP L.A. McKeown April 16, 2024
Presentation ACC 2024 Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial Presenter: David E. Kandzari April 08, 2024
News Conference News ACC 2023 HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension Todd Neale March 08, 2023
News Conference News ACC 2022 SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures Todd Neale April 08, 2022
Presentation ACC 2022 Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial Presenter: Felix Mahfoud April 04, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO Michael O'Riordan May 16, 2021
Presentation ACC 2021 Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial Presenter: Ajay J. Kirtane May 16, 2021
News Conference News ACC 2020 Renal Denervation Lowers BP in Pivotal SPYRAL HTN-OFF MED Trial Todd Neale March 30, 2020
News Conference News ACC 2019 Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO Michael O'Riordan April 01, 2019